Welcome to the era of mindful medicine.
New Publication
Serotonergic Polypharmacology of
2-Halogenated Tryptamines
This landmark publication from Psilera's Director of Drug Discovery and Development, Jeanine Yacoub, PhD, highlights the latest pharmacological data from the unique compounds being developed at Psilera.
Psilera
At A
Glance
-
We have created and developed six separate serotonergic compound families.
-
Two patents have been issued from the USPTO covering over 1 million novel compounds.
-
The Psilera leadership team has over 100 years of combined experience in the biotech and pharmaceutical industries.
-
Our best-in-class proprietary compound library has coverage for over 1 million novel compounds.
-
Psilera’s co-founders bring over $1.5B in cumulative value created from prior start-ups.
Psilera is revolutionizing how small molecule drug discovery is done. We pioneer & engineer novel therapies through next-generation precision neuroscience.
Our neuroplastogen focused pipeline offers a spectrum of solutions to meet the evolving needs of patients.
UPCOMING EVENTS
UPCOMING EVENTS
April 24
Charlotte, NC
U.N.C. Dept. of Biological Sciences Seminar Series
Dr. Jackie von Salm has been nominated by the graduate students of the University of North Carolina Department of Biological Sciences to be the Distinguished Speaker in their seminar series. Her lecture, “Reimagining Psychoactive Natural Products as Treatments for CNS Disorders”, will illuminate the possibilities still out there in drug discovery for the next generation of innovators.
April 28 - 29
Boston, MA
Neuroscience Innovation Pharma Partnering Summit
Dr. Jackie von Salm will be speaking at the Neuroscience Innovation Pharma Partnering Summit in Boston. Focused on accelerating collaboration and partnership across neurology and psychiatry, the Summit allows key opinion leaders in the CNS space the opportunity to forge new connections. Joining her will be our EVP of Corporate Development Scott Rairigh. Together, they will continue to build Psilera’s partnering network as we move closer to the clinic. If you will be in Boston for the event and would like to connect, please message us at info@psilera.com.
June 10
Miami, FL
June 22 - 25
San Diego, CA
Oppenheimer’s CNS Day
Chris Witowski, PhD will be presenting on a panel alongside industry key opinion leaders and investors. More details to come. If you will be in Miami for the event and would like to connect, please message us at info@psilera.com.
BIO International
Chris Witowski, PhD and Magali Haas, MD/PhD will be attending BIO International Convention at the end of June. We will be sharing our latest preclinical data with a select group of industry leaders and invstors. More details to come. If you will be in San Diego for the event and would like to connect, please message us at info@psilera.com.
Sept. 15 - 17
Boston MA
Neuropsychiatric Drug Development Summit
Chief Medical Officer Magali Haas, MD/PhD, to join Dr. Jackie von Salm at the 9th Annual Neuropsychiatric Drug Development Summit. Magali will be a featured panelist as well as chair her own panel at the Summit. This event is a highlight of the fall conference schedule as the team gets to present and discuss our latest data with fellow innovators in the field. If you will be in Boston for the event and would like to connect, please message us at info@psilera.com.